Search results
Results from the WOW.Com Content Network
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion ...
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Within the year of 2014, the cost of prescriptions had increased by at least 11.4% and 58% within the last eight years. The average cost for a month supply of brand-name drugs can run up to a couple of hundred US dollars, whereas in Canada and Great Britain the same medication could cost up to $40 US dollars.
The extra cost of malpractice lawsuits is a proportion of health spending in both the U.S. (1.7% in 2002) [112] and Canada (0.27% in 2001 or $237 million). In Canada the total cost of settlements, legal fees, and insurance comes to $4 per person each year, [113] but in the United States it is over $16.
The 2007 pricing model brought "Acthar in line with the cost of treatments for other very rare diseases". [89] The cost for a course of treatment in 2007 was estimated at about "$80,000–$100,000". [89] Acthar is now manufactured through a contractor on Prince Edward Island, Canada. [91]
Here are the most expensive metros North Carolina if you are looking for a two-bedroom apartment: Asheville (Asheville, Henderson, Madison counties): $1,680 a month. Raleigh (Franklin, Johnston ...
There are reports comparing these treatments in front of each other. Restricting the research only to relapses, it seems that alemtuzumab is the most cost effective [21] while anti-CD20 monoclonal antibodies (Rituxan, Ocrevus) have the better safety vs. efficacy profile [22]
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).